<DOC>
	<DOCNO>NCT01879917</DOCNO>
	<brief_summary>The purpose study investigate effect safety liraglutide 1.8 mg daily compare placebo 52 week change beta-cell function patient newly diagnose type 1 diabetes adjunctive therapy insulin treatment .</brief_summary>
	<brief_title>Liraglutide Newly Onset Type 1 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 1 diabetes accord WHO criterion diagnose â‰¤ 6 week visit 0 Age 18 40 year inclusive Postprandial Cpeptide &gt; 0.2 nmol/l follow sustacal meal test Able understand write patient information give inform consent Type 2 diabetes Body mass index &lt; 20 kg/m2 Pregnancy unwillingness use safe contraceptive Compromised kidney function ( eGFR &lt; 60 ml/min/1,73m2 ) , dialysis kidney transplantation visit 0 Liver disease elevate plasma alanine aminotransferase ( ALT ) &gt; three time upper limit normal visit 0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>c-peptide</keyword>
	<keyword>insulin</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>Newly onset</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Type 1</keyword>
	<keyword>Beta cell</keyword>
	<keyword>Autoimmune</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Meal test</keyword>
</DOC>